18889881171
Kalkine 0
countryflagUS
Logi

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Lyell Immunopharma Inc

Healthcare US LYEL

0.4664USD
0.0014(0.30%)

Last update at 2025-04-04T18:48:00Z

Day Range

0.440.50
LowHigh

52 Week Range

1.323.97
LowHigh

Fundamentals

  • Previous Close 0.47
  • Market Cap706.18M
  • Volume452730
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-218.28600M
  • Revenue TTM0.07M
  • Revenue Per Share TTM-
  • Gross Profit TTM 84.68M
  • Diluted EPS TTM-0.9

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-250M-200M-150M-100M-50M0M50M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M100M200M300M400M500M600M700M800M900M1000M1100M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-150M-100M-50M0M50M100M150M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-180M-160M-140M-120M-100M-80M-60M-40M-20M0M20M40M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -183.11800M -250.21900M -204.47200M -129.37700M
Minority interest - - - -
Net income -4.75400M -285.50100M -198.53300M -121.25600M
Selling general administrative 117.31M 89.06M 46.88M 39.15M
Selling and marketing expenses - - - -
Gross profit 84.68M 10.65M 7.76M 0.66M
Reconciled depreciation 18.02M 13.62M 4.29M 1.26M
Ebit -183.11800M -214.77600M -211.93700M -102.08900M
Ebitda -165.09800M -164.70500M -207.64300M -100.83300M
Depreciation and amortization 18.02M 50.07M 4.29M 1.26M
Non operating income net other - -36.60800M - -
Operating income -183.11800M -214.77600M -211.93700M -102.08900M
Other operating expenses 276.50M 225.43M 219.69M 102.75M
Interest expense - 1.17M 5.94M 0.00000M
Tax provision - - - -
Interest income 7.05M 1.17M 5.94M 8.12M
Net interest income 7.05M 1.17M 5.94M 8.12M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -178.36400M 35.28M -5.93900M -8.12100M
Total revenue 84.68M 10.65M 7.76M 0.66M
Total operating expenses 276.50M 225.43M 219.69M 102.75M
Cost of revenue - - - -
Total other income expense net -178.36400M -35.44300M 7.46M -27.28800M
Discontinued operations - - - -
Net income from continuing ops -183.11800M -250.21900M -204.47200M -129.37700M
Net income applicable to common shares -183.11800M -250.21900M -208.05400M -130.52100M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 750.03M 937.56M 1127.41M 908.28M 555.63M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.46M 11.14M 11.49M 4.93M 4.21M
Total liab 95.08M 104.31M 197.62M 189.84M 147.58M
Total stockholder equity 654.95M 833.25M 929.79M 718.44M 408.06M
Deferred long term liab - - - - -
Other current liab 3.07M 6.71M 37.37M 30.18M 14.35M
Common stock 0.03M 0.03M 0.02M 0.00200M 0.00100M
Capital stock 0.03M 0.03M 0.02M 1010.97M 519.16M
Retained earnings -1002.11200M -767.48000M -584.36200M -334.14300M -129.67100M
Other liab - 4.11M 84.23M 89.60M 98.41M
Good will - - - - -
Other assets - 4.96M 3.95M 3.23M 2.68M
Cash 145.65M 123.55M 293.83M 140.41M 96.67M
Cash and equivalents - - - - -
Total current liabilities 34.52M 37.03M 46.74M 49.28M 22.05M
Current deferred revenue 20.36M 21.87M 4.99M 6.09M 4.51M
Net debt -82.48000M -55.85200M -226.00900M -85.83200M -69.20500M
Short term debt 6.27M 4.53M 1.17M 3.62M 0.34M
Short long term debt - - - - -
Short long term debt total 63.17M 67.70M 67.82M 54.57M 27.47M
Other stockholder equity 1657.13M 1608.31M 388.34M 41.36M 18.11M
Property plant equipment - 166.26M 120.10M 124.06M 43.70M
Total current assets 554.69M 651.29M 626.29M 617.55M 440.26M
Long term investments 48.51M 115.04M 330.53M 163.44M 68.98M
Net tangible assets - 833.25M 929.79M -292.52800M -111.10800M
Short term investments 400.58M 516.60M 320.97M 472.21M 339.38M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.82M 3.92M 3.21M 9.40M 2.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.09400M -7.59900M -1.62300M 0.26M 0.45M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.00200M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - -584.36200M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.52M 4.96M 3.95M 3.23M 2.68M
Deferred long term asset charges - - - - -
Non current assets total 195.34M 286.27M 501.12M 290.73M 115.37M
Capital lease obligations 63.17M 67.70M 67.82M 50.96M 27.12M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -11.54000M -56.06900M -222.03500M -406.38600M
Change to liabilities -83.98600M 8.31M -8.03400M 104.63M
Total cashflows from investing activities -11.54000M -121.57300M -273.51600M -422.43300M
Net borrowings - - - -
Total cash from financing activities 10.63M 401.24M 476.79M 351.16M
Change to operating activities 1.97M 14.43M 7.70M 6.18M
Net income -183.11800M -250.21900M -204.47200M -129.37700M
Change in cash -170.46000M 153.42M 42.40M -31.80300M
Begin period cash flow 294.29M 140.87M 98.47M 130.28M
End period cash flow 123.83M 294.29M 140.87M 98.47M
Total cash from operating activities -169.55500M -126.24900M -160.87400M 39.47M
Issuance of capital stock 0.00000M 391.80M 492.47M 351.34M
Depreciation 18.02M 13.62M 4.29M 1.26M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.00000M 401.24M -16.05000M -0.18500M
Other cashflows from financing activities 1.06M 9.44M 492.84M 351.34M
Change to netincome 77.56M 100.11M 39.64M 56.79M
Capital expenditures 24.28M 65.50M 51.48M 16.05M
Change receivables - - - -
Cash flows other operating - 0.02M - -
Exchange rate changes - - - -
Cash and cash equivalents changes - 153.42M - -
Change in working capital -82.01500M 4.01M -0.33600M 110.81M
Stock based compensation 81.92M 62.20M 33.26M 15.73M
Other non cash items -6.68300M 4.62M 11.99M 42.57M
Free cash flow -193.83100M -191.75300M -212.35500M 23.43M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LYEL
Lyell Immunopharma Inc		 0.0014 0.30% 0.47 - - 5883.30 1.17 2167.49 -1.2426
NVO
Novo Nordisk A/S		 -4.44 6.62% 62.66 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.842 5.72% 63.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.74 1.19% 478.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -27.19 4.45% 583.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma Inc

201 Haskins Way, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Richard D. Klausner M.D. Founder & Exec. Chairman 1952
Ms. Elizabeth Homans CEO & Director 1966
Mr. Charles W. Newton Chief Financial Officer 1971
Mr. Stephen J. Hill Chief Operating Officer 1970
Prof. Stanley R. Riddell M.D. Founder & Scientific Advisor NA
Dr. Crystal L. Mackall M.D. Founder & Scientific Advisor NA
Nellie Dillery Director of Accounting NA
Mr. Richard Goold Ph.D. Chief Information Officer 1960
Dr. Gary Lee Ph.D. Chief Scientific Officer 1977
Ellen Rose VP of Communications & Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.